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Abstract
Background: Acquired and inherent radioresistance of tumor cells is related to tumor relapse and poor prognosis –
not only in head and neck squamous cell carcinoma (HNSCC). The underlying molecular mechanisms are largely
unknown. Therefore, systemic in-depth analyses are needed to identify key regulators of radioresistance. In the
present study, subclones of the CAL-33 HNSCC cell line with different radiosensitivity were analyzed to identify
signaling pathways related to the different phenotypes.
Methods: Subclones with altered radiosensitivity were generated by fractionated irradiation of the parental
CAL-33 cells. Differences in radiosensitivity were confirmed in colony formation assays. Selected subclones
were characterized at the genomic and transcriptomic level by SKY, array CGH, and mRNA-microarray analyses.
Time-course gene expression analyses upon irradiation using a natural cubic spline regression model identified
temporally differentially expressed genes. Moreover, early and late responding genes were identified. Gene
association networks were reconstructed using partial correlation. The Reactome pathway database was
employed to conduct pathway enrichment analyses.
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Results: The characterization of two subclones with enhanced radiation resistance (RP) and enhanced radiosensitivity
(SP) revealed distinct genomic and transcriptomic changes compared to the parental cells. Differentially expressed
genes after irradiation shared by both subclones pointed to important pathways of the early and late radiation
response, including senescence, apoptosis, DNA repair, Wnt, PI3K/AKT, and Rho GTPase signaling. The analysis of
the most important nodes of the gene association networks revealed pathways specific to the radiation response
in different phenotypes of radiosensitivity. Exemplarily, for the RP subclone the senescence-associated secretory
phenotype (SASP) together with GPCR ligand binding were considered as crucial. Also, the expression of endogenous
retrovirus ERV3-1in response to irradiation has been observed, and the related gene association networks have been
identified.
Conclusions: Our study presents comprehensive gene expression data of CAL-33 subclones with different radiation
sensitivity. The resulting networks and pathways associated with the resistant phenotype are of special interest and
include the SASP. The radiation-associated expression of ERV3-1 also appears highly attractive for further studies of
the molecular mechanisms underlying acquired radioresistance. The identified pathways may represent key players
of radioresistance, which could serve as potential targets for molecularly designed, therapeutical intervention.
Keywords: Radioresistance, HNSCC, Head and neck cancer, Time-course gene expression, Gene association network,
Signaling pathway, Differentially expressed genes, Endogenous retrovirus
Background
Head and neck squamous cell carcinoma (HNSCC) de-
velops in approx. 139,000 individuals per year in Europe
with a survival rate of approx. 70 % at 1 year and approx.
40 % at 5 years after therapy [1]. More than 90 % of head
and neck cancers are classified as HNSCC and originate
from the oral cavity, nasopharynx, oropharynx, hypopha-
rynx, or larynx, respectively [2]. The major risk factors for
HNSCC are tobacco smoking, alcohol abuse, and poor
oral health [3, 4]. For oropharyngeal cancers, infection
with high-risk human papilloma viruses is another impor-
tant risk factor [5]. Thus, HNSCC is a very heterogeneous
cancer entity also in terms of therapy response. Surgical
resection followed by radio(chemo)therapy is the standard
treatment of HNSCC patient [6, 7]. In locally advanced
HNSCC, surgery is often limited by the complex anatomy
of the affected region and, therefore, definitive radioche-
motherapy is an important treatment option. However,
acquired and/or inherent radioresistance of tumor cells is
a common cause for tumor relapse and poor prognosis.
Tumor cells derived from HNSCCs after radiotherapy
have been reported to be more radioresistant than cell
lines established prior to therapy, thus strengthening the
clinical relevance of acquired radioresistance [8]. Along
these lines, it was proposed that fractionated irradiation
might preferentially eradicate radiosensitive cells, whereas
radioresistant cells remain largely untouched. Accordingly,
recurrent tumors mostly consist of radioresistant cells [8].
Although different potential mechanisms of radioresis-
tance have been proposed and extensively studied, the
underlying molecular details remain largely unknown [9].
Systemic in-depth analyses are needed in order to identify
the master regulators of acquired radioresistance, which
could serve as potential biomarkers and future therapeutic
targets in novel combined modality approaches.
In this study, we characterized two subclones (#303
and #327) derived from the CAL-33 HNSCC cell line,
which were generated by fractionated radiation treat-
ment of the parental cells. CAL-33 is an HPV-negative
HNSCC cell line that has been established by Gioanni et
al. (1988) from a biopsy specimen prior to treatment
from a squamous cell carcinoma of the tongue from a
male patient [10]. The subclones derived thereof differed
in radiosensitivity when compared to the parental CAL-
33 cell line. Interestingly, one subclone was significantly
more radioresistant, whereas the other one was signifi-
cantly more radiosensitive. In order to identify potential
key regulators of altered radiation sensitivity, the subclones
were characterized on the genomic and transcriptomic
level. Furthermore, time-course gene expression analyses
were performed upon irradiation, and gene association
network reconstruction and pathway enrichment analyses




The human head and neck squamous cell carcinoma
(HNSCC) cell line CAL-33 was obtained from the
German collection of microorganisms and cell cultures
(DSMZ). Cells were maintained in DMEM GlutaMAX I
medium supplemented with 10 % FCS and 1 % penicillin/
streptomycin and cultured at 37 °C/5 % CO2. Cells were
mycoplasma-free as tested by the MycoAlert (Lonza)
mycoplasma detection kit.
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Generation of clones with altered radiation resistance
In order to generate radioresistant subclones of the par-
ental CAL-33 cell line, exponentially growing CAL-33
cells were exposed to fractionated irradiation (Mueller
RT-250 γ-ray, tube Thoraeus Filter, 200 kV, 10 mA)
according to a schedule commonly used in radiotherapy:
A total dose of 20 Gy was given in daily fractions of
2 Gy 5 times per week. For each week, 2 days of recov-
ery time were included. Afterwards, cells were cloned by
limiting dilution procedure and grown for 4 to 12 weeks.
Colony forming assay
Clonogenic survival was determined in colony formation
assays as described previously [11]. Briefly, cells were
seeded into 6-well plates, allowed to adhere for 4 h, and
irradiated at 0, 1, 2, 4, 6 or 8 Gy, respectively (Mueller RT-
250 γ-ray, Thoraeus Filter, 200 kV, 10 mA). 14 days after
irradiation, colonies were fixed and stained with methy-
lene blue. Only colonies consisting of at least 50 cells were
scored. Each assay was carried out in duplicates of three
different cell densities per each irradiation dose. Results
from three independent experiments were subjected to
linear-quadratic regression analyses employing the max-
imum likelihood approach. Differences between curves
were evaluated using F-test [12].
Proliferation and cell cycle analyses
Proliferation rates were determined over a period of three
days upon seeding 20,000 cells per well into 24-well plates.
Cells were harvested by trypsinization, and total cell
numbers were determined by manual counting. Cell num-
bers were plotted against the growth time, and doubling
times were calculated by semi-log regression analyses in
the exponential growth phase. Dynamics of cell cycle
distribution upon irradiation at 4 Gy was analyzed by flow
cytometric phospho-histone H3(S10)/propidium iodide
(PI) staining as described in [13]. Briefly, cells were
collected by trypsinization and fixed in 70 % ethanol. After
extensive washing, cells were stained with anti-phospho-
histone-H3-Alexa488 (pH3(S10)) antibody (New England
Biolabs, Frankfurt, Germany) and PI/RNase staining
solution (BD Biosciences, Heidelberg, Germany). Data of
10,000 cells were recorded on an LSRII flow cytometer
(BD Biosciences), and cell cycle analyses were performed
by using FlowJo 7.6.5 software (Tree Star Inc., Ashland,
OR, USA).
Spectral karyotyping (SKY)
Metaphase chromosome spreads were prepared from un-
treated CAL-33 parental cell line and generated CAL-33
sublines. Colcemid (Roche) was added at a final concen-
tration of 0.1 μg/ml to the culture medium of exponen-
tially growing cells at a density of 6 × 106 cells per 75 cm2.
After 3 h of incubation time, cells were washed with PBS,
trypsinized, suspended in fresh culture medium followed
by hypotonic KCl treatment (75 mM) at 37 °C for 25 -
minutes. Following centrifugation, cells were resuspended
in 2–3 ml of fixation solution and approximately 40–50 μl
of cell suspension was dropped on several microscope
slides. After one week of ageing at room temperature,
spectral karyotyping was performed as described by
Hieber et al. [14]. The karyotype of each cell line was
determined based on a minimum of 15 metaphases.
Chromosomal aberrations were detectable by color junc-
tions within affected chromosomes. Spectral imaging and
image analysis were performed with a SpectraCube system
and SkyView imaging software (both from Applied Spec-
tral Imaging).
Genomic copy number typing (array CGH)
In order to characterize copy number changes of parental
CAL-33 and generated CAL-33 sublines, array compara-
tive genomic hybridization analysis (array CGH) was
performed on high-resolution oligonucleotide-based Sure-
Print G3 Human 180 k CGH microarrays (AMADID
252206, Agilent Technologies). DNA from non-irradiated
samples was isolated using the QIAamp DNA Mini Kit
(Qiagen). The DNA concentration was quantified with the
NanoDrop 1000 Spectrophotometer (Thermo Fisher
Scientific, Germany). Slight modifications of the original
Agilent array CGH protocol were introduced. 250 ng
isolated cell line DNA and 250 ng sex-mismatched normal
reference DNA (Promega) were labeled with Cy3 and Cy5,
respectively, using the CGH labeling kit for oligo arrays
(Enzo) following the Enzo’s protocol. Microcon YM-30
columns (Millipore) were used to remove the unincorpo-
rated nucleotides. Subsequent labeled DNA hybridization,
washing and scanning of the CGH arrays were continued
according to the Agilent’s protocol. The fluorescence
intensities were extracted as text files with the Feature
Extraction software 10.7 (Agilent Technologies). Obtained
data were imported into the R statistical platform (version
3.2.2, www.r-project.org) and filtered for quality outliers
using the QA measurements generated by the Feature
Extraction software. Experimental artifacts were removed
from the array CGH data using spatial normalization as
suggested and described in MANOR R-package manual
[15] and [16]. Array CGH profiles containing a wave bias
that appear as waves in plots were removed using ridge
regression based algorithms implemented in NoWaves
R-package available from http://www.few.vu.nl/~mavd
wiel/nowaves.html [17]. Following normalization and/
or wave bias removal, data were segmented using circular
binary segmentation algorithms as implemented in DNA-
copy R-package [18] in order to detect breakpoints and
levels in single array CGH profiles [19]. Chromosomal
gains and losses were determined using CGHcall algo-
rithm implemented in CGHcall R-package [20]. To reduce
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data complexity, copy number calls were transformed into
regions using the R-package CGHregions [21].
Irradiation and sample preparation
Cells were seeded into 6-well plates and allowed to adhere
for 16 h. The numbers of plated cells were adjusted to the
incubation times: For samples collected 0.25, 2, 7, 12, and
24 h after irradiation, 3.5 × 105 cells/well were seeded,
whereas for those collected after 48, 72, and 96 h, 1.75 ×
105 cells/well were used. Cells were irradiated at 0 or 8 Gy
of gamma-irradiation (Mueller RT-250, Thoraeus Filter,
200 kV, 10 mA) at a dose rate of 1.3 Gy/min, and samples
were collected after 0.25, 2, 7, 12, 24, 48, 72, and 96 h by
scraping on ice. The washed, dry cell pellet was snap
frozen and stored at −80 °C. Samples from 3 independent
experiments were used for subsequent transcriptomic
analyses. Total RNA was isolated using the Rneasy Mini
Kit (Qiagen) including a DNase digestion step, according
to the manufacturer’s protocol. The concentration of RNA
was quantified with a Qubit 2.0 Fluorometer (Life
Technologies), and RNA integrity was confirmed with a
Bioanalyzer 2100 (Agilent Technologies). Samples with
RNA integrity number (RIN) >7 were used in subsequent
gene expression microarrays analyses.
Global gene expression profiling
Global gene expression profiling of all CAL-33 cell lines
was performed on SurePrint G3 Human Gene Expression
8x60k microarrays (Agilent Technologies, AMADID
28004) using 60 ng of total RNA according to the manu-
facturer’s protocol (one-color Low Input Quick Amp
Labeling Kit, Agilent Technologies). Raw gene expression
data were extracted as text files with the Feature Extraction
software 11.0.1.1 (Agilent Technologies). All data analysis
was conducted using the R statistical platform (version
3.2.2, www.r-project.org) [22]. Data quality assessment,
filtering, preprocessing, normalization, batch correction
based on nucleic acid labeling batches and data analyses
were carried out with the Bioconductor R-packages limma,
Agi4x44PreProcess and the ComBat function of the
sva R-package [23–25]. All quality control, filtering, pre-
processing and normalization thresholds were set to the
same values as suggested in Agi4x44PreProcess R-package
user guide [25]. Only HGNC annotated genes were used
in the analysis. For multiple microarray probes represen-
ting the same gene the optimal probe was selected accor-
ding to the Megablast score of probe sequences against
the human reference sequence (http://www.ncbi.nlm.nih.
gov/refseq/) [26]. If the resulted score was equal for two
or more probes, the probe with the lowest differential
gene expression FDR value was kept for further analyses
since only one expression value per gene was allowed in
subsequent gene association network (GAN) reconstruc-
tion analysis.
Differential gene expression analysis
The time-course differential gene expression analyses
were conducted between irradiated and control cells
(sham-irradiated) using a natural cubic spline regression
model with three degrees of freedom as described in
splineTimeR R-package [27]. Obtained p-values were
adjusted by the Benjamini-Hochberg method for false
discovery [28]. Genes with an adjusted p-value (FDR,
false discovery rate) lower than 0.05 were considered as
differentially expressed and associated with radiation
response. For the status quo experiment that compares
the derived CAL-33 clones with the parental CAL-33 cell
line, genes were considered as differentially expressed
when a log2 fold-change was higher than 0.5 and a FDR
value lower than 0.05.
Identification of early and late responding genes
Temporally differentially expressed genes with fold-change
above 2.0 or below 0.5 in any measured time points within
the first day after irradiation were considered as early
responding genes. Respectively, genes with fold-change
above 2.0 or below 0.5 within the second, third or fourth
day of irradiation were considered as late responding.
Gene association network reconstruction and
identification of important nodes in the reconstructed
networks
Temporally differentially expressed genes were subjected
to gene association network (GAN) reconstruction using
a regularized dynamic partial correlation method [29].
Pairwise relationships between genes over time were
inferred based on a dynamic Bayesian network model
with shrinkage estimation of covariance matrices as
implemented in the GeneNet R-package [30]. Analyses
were conducted with a posterior probability of 0.95 for
each potential undirected edge. Further, in order to deter-
mine the importance of each node in the reconstructed
association networks, graph topological analyses based on
centrality measures were applied [31]. Three most com-
monly used centrality measures: degree, shortest path
betweenness and closeness describing the importance of
gene in a network were combined into one centrality
measure [32]. For each gene the three centrality values
where ranked and the consensus centrality measure for
each node was defined as the mean of the three indepen-
dent centrality ranks.
Pathway enrichment analysis
The Reactome pathway database was used to conduct
the pathway enrichment analysis in order to further
investigate the functions of the selected sets of differen-
tially expressed genes [33]. Only pathways containing
not more than 600 genes and not less than 20 genes were
considered. Thereby, too general and too specific pathways
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were excluded from the analysis. Statistical significance of
enriched pathways was determined by one-sided Fisher’s
exact test. The resulting p-values were adjusted for FDR
using the Benjamini-Hochberg method.
qRT-PCR technical validation of gene expression data
For technical validation of the gene expression microarray
data, RNA samples (500 ng) were reversely transcribed
using the QuantiTect Reverse Transcription Kit (Qiagen)
according to the manufacturer’s protocol and subjected to
qRT-PCR reactions (10 μl) on a ViiA 7 qPCR system (Life
Technologies). The following Taqman® Assays were used
(Life Technologies): AKT3 (Hs00987350_m1), GADD45A
(Hs01077132_m1), MAL (Hs00360838_m1), HOPX (Hs0
4188695_m1), HYAL3 (Hs00185910_m1), TUBGCP3 (Hs
00902139_m1), RGS16 (Hs00892674_m1), TNFAIP3 (Hs0
0234713_m1). ACTB (Hs01060665_g1) and GAPDH (Hs9
9999905_m1) served as endogenous reference genes.
Relative expression levels were calculated using the ΔΔCt
method and Spearman correlation analyses with micro-
array data were performed. Validation was considered
successful for Spearman’s rho > 0.5. Additionally, the fold-
change values obtained from microarrays and qRT-PCR
were compared.
Results and discussion
Tumor relapse after radiochemotherapy in HNSCC is often
linked to intrinsic and/or acquired radioresistance of tumor
cells. However, the underlying molecular mechanisms
remain largely unknown [9]. To gain knowledge on this
fundamental and clinically relevant process, we established
an in vitro model of acquired phenotypes of discrepant
radiosensitivity in CAL-33 cells. The underlying molecular
mechanisms were investigated by static and dynamic global
mRNA expression analyses with subsequent network re-
construction and pathway enrichment analyses.
CAL-33 subclones with different phenotypes of
radiosensitivity and cytogenetic characteristics
The parental cell line CAL-33 was repeatedly irradiated in
order to generate subclones with different phenotypes of
radiosensitivity. To analyze acquired alterations in radio-
sensitivity of the derived CAL-33 subclones, long-term
survival upon gamma-irradiation was assessed by colony
formation assays (Fig. 1). For further analyses we selected
two subclones. Both subclones #303 and #327 showed
statistically significant differences (p-values < 0.0001) when
compared to the parental CAL-33 cells. Interestingly, sub-
clone #303 showed increased radiosensitivity (sensitive
Fig. 1 Dose-survival curves of parental CAL-33 cell line and derived subclones. The linear-quadratic cell survival curves were fitted to the measured
data using maximum-likelihood method. Both subclones (SP and RP) showed statistically significant difference (p-values < 0.0001) in response to
ionizing radiation compared to the parental CAL-33 cell line
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phenotype, SP), whereas subclone #327 was more radio-
resistant (resistant phenotype, RP) – particularly in the
dose range > 4 Gy.
At first glance, the emergence of more radiation sensi-
tive subclones appears unexpected and might be related to
clonal evolution that was initiated by the irradiation-
induced genomic alterations and that might occur at sub-
lethal doses. This phenomenon has also been observed in
previous studies [34, 35]. In comparison to other HNSCC
cell lines, CAL-33 is very radioresistant a priori and this
might explain why it appears to be very difficult to gene-
rate subclones with an even more resistant phenotype.
To analyze structural and numerical chromosomal
aberrations in comparison to the parental cell line, the
subclones were cytogenetically characterized by SKY ana-
lyses. Structural and numerical aberrations identified by
SKY in the parental CAL-33 cell line involved chromo-
somes 3, 7, 8, 9, 16, 18, 20, X, and Y (Fig. 2a). Structural
and numerical aberrations of the SP subclone included
chromosomes 2, 3, 7, 8, 9, 11, 16, 18, 20, 21, X, and Y
(Fig. 2b). Chromosomes 1, 3, 4, 5, 7, 8, 9, 14, 16, 18, 20, X,
and Y were affected by aberrations in subclone RP (Fig. 2c).
The obtained SKY results were complemented with
copy number analysis by array CGH (Fig. 3 and Additional
file 1: Table S1). Array CGH analysis identified 173 regions
with aberrant copy number status from which 78, 111 and
132 regions were affected by DNA gains or DNA losses in
the CAL-33 parental cells, SP, or RP subclones, respec-
tively (Fig. 3 and Additional file 1: Table S1 and Additional
file 2: Table S2). 68 copy number alterations (for SP) and
85 copy number alterations (for RP) were different from
the parental CAL-33 cell line. Cytogenetic studies of both
clones showed distinct genomic changes in comparison to
the parental cell line indicating genomic key alterations
for irradiation-related phenotypes on chromosomes 1, 2,
3, 4, 5, 8, 11, 14, 16 and 21. In addition, recurrent CAL-
33-specific alterations on chromosomes 3, 7, 18, X and Y
were observed showing the authenticity of the newly
generated cell lines.
Analysis of proliferation rates and cell cycle distribution
Proliferation rate and cell cycle distribution are impor-
tant factors, which can affect radiosensitivity and/or
resistance. Accordingly, we performed proliferation and
cell cycle analyses. In comparison to CAL-33 parental
cells, both subclones displayed prolonged doubling times
(29 h for subclone SP, 30 h for subclone RP, and 24 h for
the parental cell line, Additional file 3: Figure S1, A).
This might be due to the observation that under expo-
nential growth conditions, the percentage of mitotic cells
in both subclones was decreased (2.1 % for subclone SP,
1.5 % for subclone RP, and 2.9 % for the parental cells),
but fails to explain the differences in radiosensitivity
(Additional file 3: Figure S1, B). With regard to irradiation-
induced G2-arrest, the sensitive subclone SP revealed
virtually identical dynamics as the parental CAL-33 cells,
whereas in the resistant subclone RP G2-arrest was initially
delayed, but also reached its maximum around 12 h after
irradiation, and afterwards appeared to be prolonged
(Additional file 3: Figure S1, C). In fact, prolonged cell
cycle arrest can contribute to radioresistance as cells have
more time to repair irradiation-induced DNA damage.
However, extended cell cycle arrest can also be indicative
for delayed DNA repair. In order to address the mecha-
nisms underlying radioresistance on a molecular level,
next we therefore performed unbiased transcriptome ana-
lyses of the CAL-33 subclones.
mRNA gene expression analysis of the CAL-33 subclones
Microarray analyses allowed the identification of diffe-
rences in basal gene expression levels between the derived
subclones and the parental CAL-33 cell line. We identified
523 and 1292 differentially expressed genes (FDR < 0.05)
for clones SP and RP, respectively, whereas 361 of the
genes were overlapping (Additional file 4: Table S3). It is
interesting to note that the RP clone exhibited more
pronounced transcriptional differences than the SP clone.
Eight of the differentially expressed genes (SP and/or RP
clone versus the parental CAL-33 cell line) were arbitrarily
chosen for technical validation of the microarray data. Cor-
relation analysis between qRT-PCR and microarray data
showed a strong correlation for seven out of eight validated
genes (Additional file 5: Table S4). The microarray and
qRT-PCR derived fold-changes were in a good agreement.
Subsequently, the differentially expressed genes were
subjected to pathway enrichment analyses in order to
determine pathways common or specific to the radioresis-
tant or radiosensitive phenotype. In total, 65 and 455
pathways were significantly enriched (FDR < 0.1) for the
SP and RP clone, respectively (Additional file 6: Table S5).
The top 100 identified pathways ordered according to the
highest matching (percentage of differentially expressed
genes of all genes in a pathway) were grouped into major
pathways (Table 1).
This resulted in a set of commonly deregulated path-
ways compared to the parental cell line but not specific
for a particular phenotype of radiation sensitivity. More-
over, pathways specific to the radiosensitive or radioresis-
tant phenotype were identified. These comprised mainly
pathways that are known to be affected by ionizing irra-
diation in HNSCC [36–38].
Integration of copy number changes with differentially
expressed genes
To verify whether the aberrant expression of genes in the
SP and RP subclones can be explained by the observed
copy number changes, integration of genomic (array CGH
data) and transcriptomic data was performed. For subclone
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Fig. 2 SKY results of the CAL-33 cell lines. The yellow arrows point the common for all CAL-33 cell lines marker chromosomes. The additional
chromosomal rearrangements in analyzed clones compared to the parental CAL-33 cells are marked with white arrows. Structural and numerical
aberrations in the parental CAL-33 cell line (a) involve chromosomes 3, 7, 8, 9 16, 18, 20, X, and Y. Aberrations of subclone SP (b) include chromosomes
2, 3, 7, 8, 9, 11, 16, 18, 20, 21, X, and Y. Chromosomal aberrations of subclone RP (c) affect chromosomes 1, 3, 4, 5, 7, 8, 9, 14, 16, 18, 20, X, and Y
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SP, we identified 18 genes with DNA gains being up-
regulated and 31 genes with DNA losses being down-
regulated, whereas for subclone RP, 44 up-regulated genes
showed copy number gains and 5 genes with copy number
losses were down-regulated (Table 2).
This integrative data analysis of DNA copy number and
gene expression followed by pathway enrichment analysis
allowed us to identify related pathways encompassing
signaling by Rho GTPases as one of the deregulated
pathways in the SP subclone. At the same time we
observed DNA loss and downregulation of the TIAM1
gene that belongs to the Rho GTPases signaling pathway.
Yang et al. recently showed that high expression of TIAM1
is associated with poor clinical outcome in patients with
HNSCC [39]. Similarly, for the RP subclone a gain and
upregulation of RAD1 and RICTOR genes was observed
which is in accordance with the deregulation of the
homologous recombination and PI3K signaling pathways in
Table 1 Significantly enriched pathways of genes differentially expressed in subclones SP and RP compared to the parental CAL-33
cells
CAL-33 SP vs parental Common signalling pathways CAL-33 RP vs parental
Transmembrane transport of small molecules Signaling by VEGF Nonhomologous end-joining (NHEJ)
GPCR ligand binding Extracellular matrix organization Homologous DNA pairing and strand exchange
Signaling by Rho GTPases RNA polymerase III transcription initiation CD28 dependent PI3K/Akt signaling
Interferon signaling NOTCH1 intracellular domain regulates
transcription
Signaling by interleukins
Senescence-associated secretory phenotype (SASP)
NOD1/2 signaling pathway




Pathways common (middle) and specific to the radiosensitive (left) or radioresistant (right) phenotype are shown. The corresponding genes and their direction of
regulation (up/down) are listed in Additional file 4: Table S3 and Additional file 6: Table S5
Fig. 3 Array CGH profiles of the CAL-33 cell lines. The array CGH profiles of all of the three cell lines show copy number alterations on several
chromosomes: (a) parental CAL-33 cell line, (b) subclone SP, (c) subclone RP. The green bars (starting from the top) represent DNA copy number
gains at the corresponding position in the genome, whereas the red bars (starting from the bottom) indicate DNA copy number losses. Bars reaching
beyond the middle axis (probability >0.5) were called as gains or losses
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HNSCC as previously described in [40]. For both of those
clones a gain and upregulation of the TLR4 gene and the
deregulation of the toll-like kinases signaling pathway in-
cluding upregulation of the genes PLCG2, TAB3, RPS6KA2
has been detected. Even though contradictory reports exist,
the overexpression of TLR4 and activation of related path-
way has been described to promote HNSCC tumor deve-
lopment and to ensure tumor protection from the immune
system [41].
Time-dependent gene expression in response to ionizing
radiation in CAL-33 clones
It was hypothesized that CAL-33 subclones with diffe-
rent phenotypes of radiosensitivity also show differences
in gene expression profiles in response to irradiation.
Therefore, we performed differential time-course micro-
array analyses between irradiated (8 Gy) and sham irra-
diated control cells. 7299, 6980, and 8111 genes were
differentially expressed in the CAL-33 parental, SP, and
RP subclones, respectively (Table 3). Although the num-
ber of differentially expressed genes after irradiation with
8 Gy was comparable for all cell lines studied, appro-
ximately 50 % of the affected genes were not identical.
More than 1000 genes were exclusively involved in the
radiation response of each of the CAL-33 cell clones
(Fig. 4). The entirety of differentially expressed genes in
response to ionizing radiation is listed and compared for
all CAL-33 cell lines in Additional file 7: Table S6.
To identify common and separate pathways of the
radiation response, pathway enrichment analyses were
Table 2 Integration of differentially expressed genes with array
CGH data
CAL-33 SP (#303) CAL-33 RP (#327)
Gene name FC Gene name FC
PTGS1 16.417 gain PTGS1 20.52 gain
TLR4 10.333 IL7R 10.643
SLC2A6 7.167 SLC2A6 7.13
TNC 5.478 SLC12A7 6.931
PHF11 4.886 COL5A1 6.608
PAPPA 4.594 CERCAM 6.381
MX2 4.457 PDZD2 5.726
LHFP 4.442 PTGER4 5.05
RGCC 4.285 STXBP1 4.377
GTF2F2 3.767 INPP5E 3.797
BACE2 3.755 NKD2 3.785
NEK3 3.564 SLC1A3 3.784
MSANTD3 3.198 RICTOR 3.675
FNDC3A 2.971 PTGES 3.409
RC3H2 2.77 MVB12B 3.381
INPP5E 2.584 CDK5RAP2 3.362
RPL7A 2.543 PRRC2B 3.155
UFM1 2.485 SEC16A 2.948
SLC25A29 0.263 loss RC3H2 2.855
RCOR1 0.297 USP20 2.714
HLCS 0.305 RPL7A 2.59
CCDC85C 0.318 CARD9 2.572
IPO5 0.322 TOR1B 2.529
WRB 0.326 TRAF1 2.524
PIGP 0.329 QSOX2 2.492
CDCA4 0.36 TLR4 2.473
ZBTB42 0.361 UGCG 2.463
EVA1C 0.37 ZBTB43 2.396
BTBD6 0.37 C9orf9 2.327
TTC3 0.374 RAD1 2.255
CLN5 0.388 TRIM32 2.241
CCNK 0.389 PTRH1 2.221
DSC3 0.389 CEP72 2.208
PPP1R13B 0.389 DAP 2.035
DYRK1A 0.393 C9orf114 2.019
SIVA1 0.4 SDHA 2.013
BRF1 0.404 DOLPP1 1.997
IMPACT 0.41 RALGPS1 1.996
IFNGR2 0.416 SURF1 1.958
TIAM1 0.423 MTRR 1.855
PCCA 0.426 C5orf42 1.849
EML1 0.432 ANKRD33B 0.609
Table 2 Integration of differentially expressed genes with array
CGH data (Continued)
HMGN1 0.439 OR4C6 0.576
SETD3 0.441 NPR3 0.43
OSBPL1A 0.462 GOLGA6L6 0.505 loss
IFNAR2 0.54 ZNF480 0.532
LAMA3 2.1 NBPF10 1.909
CRIP1 2.463 TPTE 2.342
CDH2 5.373 NBPF9 2.945
Detailed information on identified genes, their CNA status and corresponding
fold changes are presented
Table 3 Comparison of detected and differentially expressed
genes after irradiation for analyzed cell sublines
CAL-33 (8 Gy vs sham-irradiated) Parental
cell line
Subclone SP Subclone RP




Number of genes in the network 6256 5709 6859
5 % top genes 313 285 343
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performed on early and late responding genes, respec-
tively (Additional file 8: Table S7). The most interesting
pathways with regard to their known role in radiation
response were grouped in to major pathways (Table 4).
It is interesting to note that all cell lines share a set of
deregulated pathways (Table 4). In addition, for each of
the radiosensitivity phenotypes (parental, SP, RP) specific
pathways were observed. The early responses in gene
expression include interferon signaling and in particular
for the resistant phenotype the cellular response to hy-
poxia which is known for a long time to have a crucial role
in radioresistance [42, 43]. Also, some other pathways
from an early gene expression response that are involved
in DNA repair, cell cycle, cellular response to stress and
apoptosis impact on survival after irradiation and there-
fore contribute to radioresistance [9, 44–46].
Deregulated pathways related to late responding genes
include EGFR- and PI3K/AKT signaling that were already
linked to poor clinical outcome and therapy response in
HNSCC [47–49] in association with ERBB2, ERBB3 and
ERBB4 co-expression [50–52]. Interestingly, also involve-
ment of ERBB2 and EERB4 receptor signaling was observed
in all cell lines as a late response to ionizing radiation.
Further late responding pathways include toll-like receptor
cascades, interleukin signaling, NF-kB activation and inter-
feron signaling all of which are frequently detected after
treatment with ionizing radiation [53, 54]. However, the
role of interleukin signaling and immune response is largely
unknown so far. This also applies to cellular senescence
and the impact of senescence pathways on radioresistance
that were also discovered as late responding pathways in
our CAL-33 subclones. Although evidence exists that
senescence might be associated with the disruption of the
tissue microenvironment leading to the secretion of
senescence-associated pro-inflammatory factors and to the
development of a pro-oncogenic environment [34] its role
in radioresistance in rather unclear so far.
Gene association network reconstruction and network
analysis
To go beyond pathway enrichment analyses of differen-
tially expressed genes, gene association networks were
reconstructed. Parameters of the obtained networks
(provided as igraph R-objects in Additional file 9: File S1)
for all three CAL-33 cell lines are presented in Table 3.
Subsequently, the combined topological centrality mea-
sure was used to characterize the biological importance of
genes in the reconstructed association networks. We iden-
tified nodes (genes) that are likely to control the network
by combining three network centrality measures: degree,
Fig. 4 Venn diagram displaying commonly and exclusively differentially
expressed genes of each CAL-33 cell line after irradiation with 8 Gy
Table 4 Significantly enriched pathways of early and late
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closeness and shortest path betweenness [32, 55]. The 5 %
of the highest ranked genes (listed in Additional file 10:
Table S8) were mapped to the Reactome pathways to
further evaluate their biological roles. The top ten pathways
according to the FDR values are listed in Table 5. All iden-
tified pathways are listed in Additional file 11: Table S9.
Two of the detected pathways, signaling by Rho GTPases
and signaling by Wnt, were in common for all three sub-
clones exposed to irradiation (Table 5). However, most of
the pathways were different for the individual subclones.
For the parental cell line, we additionally detected pathways
associated with cellular response to stress, signaling by
Table 5 The top pathways after mapping of 5 % highest ranked genes from the reconstructed gene association networks to the
Reactome pathways
Pathway Genes
CAL-33 parental Generic transcription pathway CCNC, NR4A3, ZNF248, ZNF302, ZNF350, ZNF417, ZNF431, ZNF543,
ZNF621, ZNF710, ZNF735
Cellular responses to stress BAG4, CDKN2D, DEDD2, GABARAPL2, HSPA1A, MAPK10, RBX1
Diseases of signal transduction CBL, CCNC, CTBP2, FOXO4, RBX1, TGFB1
EPH-ephrin mediated repulsion of cells CLTCL1, EFNA5, SRC
Neurotransmitter release cycle CHAT, SNAP25, STXBP1
O-linked glycosylation ADAMTSL5, CFP, ST3GAL3, THBS2
Signaling by EGFR CBL, FOXO4, NF1, PAG1, RBX1, SPRY1, SRC
Signaling by Wnt CTBP2, DAAM1, FRAT1, RAC2, RBBP5, RBX1, SOX3
Signaling by Rho GTPases ABR, CENPA, DAAM1, PKN3, RAC2, RANGAP1, SRC
Cytochrome P450 - arranged by substrate type CYP17A1, CYP3A4, CYP4A11
SP subclone Axon guidance APH1A, DPYSL3, HSP90AB1, ITGA9, LAMTOR2, NRG1, PLXNA4,
PPP2CA, PSPN, RAC1, RDX, RGMB
Generic transcription pathway AKT2, LAMTOR2, MED26, TBL1XR1, ZNF302, ZNF394, ZNF431,
ZNF561, ZNF680, ZNF691, ZNF750, ZNF774
Cell cycle CDKN2D, EP300, MASTL, MAU2, MCM4, NUPL2, PPP2CA, RAD21,
RANGAP1, SKA2, SYCP1
Chromatin organization ATXN7, EP300, HIST3H2A, KDM4D, KDM5D, SUPT20H, TBL1XR1
Diseases of signal transduction AKT2, APH1A, BCR, CTBP2, EP300, NRG1, PPP2CA, TBL1XR1
Signaling by Wnt AKT2, CCDC88C, CTBP2, EP300, PLCB1, PPP2CA, RAC1, RNF146
Semaphorin interactions DPYSL3, HSP90AB1, PLXNA4, RAC1
Glycolysis ALDOC, GCK, PPP2CA
Regulation of beta-cell development AKT2, GCK, IAPP
RHO GTPases activate WASPs and WAVEs NCKIPSD, RAC1, WAS
RP subclone Signaling by Rho GTPases ABR, ACTB, ARHGAP35, ARHGEF7, BCR, HIST1H2BJ, HIST1H2BL,
HIST2H2BE, INCENP, ITSN1, NDE1, OBSCN, RHOT1, SRGAP1, WAS
Cell Cycle ANAPC11, BLM, CDKN1A, CDKN2D, FZR1, HIST1H2BJ, HIST1H2BL,
HIST2H2BE, INCENP, KIF23, MAU2, NDE1, NUP62, POM121,
PSMC3IP, TK2, WHSC1
Senescence-associated secretory phenotype (SASP) ANAPC11, CDKN1A, CDKN2D, FZR1, HIST1H2BJ, HIST1H2BL, HIST2H2BE
GPCR ligand binding CCL19, GPR132, MC1R, MLN, OPN1SW, OPRL1, PTCH2, PTGDR,
PTGER1, TAS2R14, TAS2R19, TAS2R45, TBXA2R, WNT10B
Transcriptional regulation by small RNAs HIST1H2BJ, HIST1H2BL, HIST2H2BE, NUP62, POM121
G alpha (12/13) signaling events ABR, ARHGEF7, ITSN1, OBSCN, TBXA2R
Post-translational protein modification ADAMTS19, ARSB, ARSG, BLM, CFP, CNIH1, CNIH2, GALNT10, NUP62,
POM121, ST3GAL3
DNA repair ACTB, BLM, CHD1L, DTL, ERCC6, HIST1H2BJ, HIST1H2BL, HIST2H2BE,
WHSC1
Signaling by Wnt HIST1H2BJ, HIST1H2BL, HIST2H2BE, NFATC1, PLCB1, SOX3, TCF7L2,
TMED5, WNT10B
Assembly of the primary cilium BBS10, CC2D2A, NDE1, NPHP1, PDE6D, TCTEX1D2, TTC30B
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EGFR, and cytochrome P450. The most important path-
ways in the SP subclone were associated with axon gui-
dance, chromatin organization and semaphorin, whereas
for the RP subclone the senescence-associated secretory
phenotype (SASP) together with GPCR ligand binding
were considered as crucial. The co-occurrence of the
SASP and GPCR signaling pathways, that are known
to be connected [56], indicate that the identification of
those pathways might not be accidental and suggest a
high importance for the radiation resistant phenotype.
In future experiments more HNSCC cell lines should
be analyzed.
Fig. 5 First neighborhood of the ERV3-1 gene extracted from the reconstructed gene association networks
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Expression of endogenous retrovirus and related
pathways
The analysis of differentially expressed genes between the
RP and SP subclones and the parental cell line revealed
the ERVMER34-1 gene as differentially expressed in both
clones. Approximately 8 % of the human genome consists
of endogenous retroviruses (ERVs) that have been derived
from exogenous retroviruses following infection and
DNA integration into germ line cells [57, 58]. Although
most of the ERV sequences have defective structures,
some of ERV genes still have an open reading frame
(ORF) and protein expression [59]. ERV genes can pro-
mote homologous and non-homologous recombination
and therefore, may introduce new mutations [60, 61].
Furthermore, ERVs may lead to genome instability, and
contribute to tumor initiation and progression [62]. The
expression of ERV genes has been demonstrated in vari-
ous cancers, including breast, ovarian, prostate and mel-
anoma [63–66]. The differential gene expression analyses
of the subclones in comparison to the parental CAL-33
cells revealed ERVMER34-1 gene as differentially expressed
in both derived clones (Additional file 4: Table S3). Subse-
quently, we tested whether any of the retroviral genes were
differentially expressed in response to ionizing radiation.
Apart from ERVMER34-1, we were able to identify another
endogenous retroviral gene, ERV3-1, that was temporally
differentially expressed following radiation. The time
dependent expression of those genes suggests ERV3-1 ex-
pression to be associated with the radiation response,
whereas ERVMER34-1 expression exhibits rather random
fluctuations (Additional file 12: Figure S2 and Additional
file 13: Figure S3). Thus, the ERV3-1 expression clearly
implies a possible association with the radiation exposure.
The radiation-associated upregulation of ERV3-1 is dem-
onstrated for all subclones starting from the second day of
irradiation. To our knowledge, the expression of ERV3-1
following radiation and its influence on radiation resistance
has not been addressed in detail so far. A recent study by
Lee et al. [67] has demonstrated an increase in the expres-
sion of ERV3-1 (HERV-R) env related to a fractionated
exposure to γ-radiation in radioresistant A549 lung cancer
cells but not in less radioresistant H460 cells. The presented
results raise the question whether overexpression of ERV3-
1 might be involved in the radiation response of HNSCC
cells. To gain knowledge about the potential gene interac-
tions with the ERV3-1 gene we used the gene association
networks reconstructed for all CAL-33 subclones and
extracted the putative direct or indirect ERV3-1 interaction
partners resulting in the first neighborhood genes of ERV3-
1 differ between the three analyzed cell lines (Fig. 5). The
largest first neighborhood gene association network can be
observed for the RP subclone where 29 genes are linked to
ERV3-1. For the CAL-33 parental cell line and the SP
subclone the first neighborhood gene association network
consist only of three (OR2A2, U2AF1L4, C11orf94) and
one (FEEH2) potential association partners, respectively.
The considerably larger first neighborhood of the ERV3-1
gene for the RP cells suggests a more important role of this
gene for acquired radiation resistance. In addition, a Reac-
tome pathway enrichment analysis revealed that the first
neighborhood genes of the ERV3-1 gene in RP cells were
associated with GPCR signaling (DRD4, OPN1MW, TBX
A2R), transmembrane transport of small molecules (ATP
1B2, AZGP1, SLC22A17), generic transcription pathway
(ZNF419, ZNF550, ZNF782), signaling by Rho GTPases
(NCKIPSD), and cell cycle (MAX). However, to our know-
ledge, the interaction partners of the ERV3-1 gene have not
been studied in detail so far, which makes an interpretation
difficult and highly speculative at this time. Also further
studies have to be performed in order to validate the gene
associations with ERV3-1independently.
Conclusion
In conclusion, the present study presents comprehensive
gene expression data of CAL-33 subclones of different
radiosensitivity. Based on these data networks have been
identified that are linked to the radiation response
phenotypes. The pathways associated with the resistant
phenotype are of special interest focusing on the
senescence-associated secretory phenotype (SASP) to-
gether and GPCR ligand binding. Also, the radiation-
associated expression of the endogenous retrovirus
ERV3-1 appears highly attractive for further studies on
the molecular mechanisms of acquired radioresistance.
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